FundedIQ
Biotechnology

PathoQuest: Funding, Investors & Team (Sep 2026)

PathoQuest SAS, a spin off of Institut Pasteur, is a biotechnology company offering a game changing metagenomics approach to improving the breadth of pathogen detection. The company’s proprietary next generation sequencing (NGS) based testing approach delivers actionable reports to clinicians, biologists and biopharmaceutical quality assurance managers/production managers. PathoQuest’s proprietary sample preparation, and its comprehensive database of pathogens genomic information, enables clinicians and biopharma companies to overcome the current limitation of infectious agent detection. PathoQuest’s Viral Safety testing service, directed towards biopharmaceutical companies, is the company’s first commercial application of its testing approach and has quickly established a revenue stream for the company from several major biopharma companies.

www.pathoquest.com LinkedIn Paris, France 11-50 employees
Total raised
$17.4M
Rounds
1
Latest
Series B
Nov 2021

PathoQuest has raised $17.4M across 1 funding round on record, the most recent a Series B of $17.4M announced in Nov 2021.

That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.

PathoQuest Company Profile and Key Stats

Total funding raised
$17.4M
across 1 round on record
Funding rounds on record
1
Latest funding round
Series B
$17.4M in Nov 2021
Employees
11-50
reported band
Headquarters
Paris, France

Latest funding round on record: Nov 2021.

PathoQuest Funding Rounds

Date
Round
Amount
Series B
$17.4M

PathoQuest Founders and Leadership Team

Name
Role
Contact
Jean Francois Brepson
CEO

No contact details are on record for this team yet.

PathoQuest Funding Compared to Other Biotechnology Startups

Segment
Companies
Median round
4,182
$8.0M
1,706
$6.7M
4,307
$30M

PathoQuest's latest round of $17.4M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.

Funded Startups Like PathoQuest in Biotechnology and Paris

Companies Similar to PathoQuest

Brenus Pharma is a platform that uses allogeneic techniques to create immune therapy with the goal of…

Series A $12.6M

TISSIUM is a privately owned medical device company based in Paris, France that is dedicated to the rapid…

Series D $34.0M

NicOx is a biopharmaceutical company that focuses on creating and selling nitric oxide-donating drugs for…

Undisclosed round $6.9M

Advicenne is a specialty pharmaceutical company dedicated to improving the lives of patients who suffer from…

Undisclosed round $1.7M

One Biosciences was founded in Paris, Ile-de-France, France by Magali Richard, David Schilansky, and Céline…

Undisclosed round

Inventiva Pharma is a biopharmaceutical company in the clinical stage that focuses on creating oral small…

Undisclosed round $120M

NETRIS Pharma develops therapeutic molecules for treating cancer by targeting dependence receptors for the…

Undisclosed round $8.4M

AbIONYX Pharma is a biotechnology company that is focused on providing innovative therapies for indications…

Undisclosed round $11.6M

Founded in 2003, Nanobiotix is at the forefront of nanomedicine and is committed to revolutionizing patient…

Undisclosed round $116M

Theraclion specializes in high-tech medical equipment using high-intensity focused ultrasound (HIFU). They…

Undisclosed round $7.0M

Abivax, a clinical stage biotechnology company, is mobilizing the body’s natural immune machinery to treat…

Undisclosed round $45.0M

AB Science was established in 2001 by a group of individuals in the medical and business fields who are…

Undisclosed round $3.7M

PathoQuest Funding FAQs

What does PathoQuest do?

PathoQuest SAS, a spin off of Institut Pasteur, is a biotechnology company offering a game changing metagenomics approach to improving the breadth of pathogen detection. The company’s proprietary next generation sequencing (NGS) based testing approach delivers actionable reports to clinicians, biologists and biopharmaceutical quality assurance managers/production managers. PathoQuest’s proprietary sample preparation, and its comprehensive database of pathogens genomic information, enables clinicians and biopharma companies to overcome the current limitation of infectious agent detection. PathoQuest’s Viral Safety testing service, directed towards biopharmaceutical companies, is the company’s first commercial application of its testing approach and has quickly established a revenue stream for the company from several major biopharma companies.

How much funding has PathoQuest raised?

PathoQuest has raised $17.4M across 1 round on record. The most recent is a Series B of $17.4M announced in Nov 2021.

When did PathoQuest last raise funding?

PathoQuest's most recent funding round on record is a Series B of $17.4M, announced in Nov 2021.

Who is the CEO of PathoQuest?

Jean Francois Brepson is listed as CEO at PathoQuest.

Where is PathoQuest headquartered?

PathoQuest is based in Paris, Ile-De-France, France.

How many employees does PathoQuest have?

PathoQuest is in the 11-50 employee band.

How does PathoQuest's funding compare to other Biotechnology startups?

PathoQuest's latest round of $17.4M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.

About FundedIQ's PathoQuest Funding Data

FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.

Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for PathoQuest is left off this page rather than filled in.

14-day free trial · Cancel anytime

Know who just raised. Then know who to reach.

Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.

Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.